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Abstract 
Introduction: Multidrug resistance (MDR) is a condition defined by the cross-
resistance to several non-structurally related drugs, representing one of the major setbacks to 
the success of chemotherapy. One of the best studied MDR mechanisms is the overexpression 
of efflux pumps, such as P-glycoprotein (Pgp), multiple resistance-related protein 1 (MRP-1) 
and major vault protein (LRP). These proteins confer resistance to a large spectrum of similar 
substrates, despite their different extrusion mechanisms. Pharmacologic inhibition of MDR 
transporters is the major strategy to overcome this phenotype. Verapamil is an L-type 
calcium-channel blocker and a modulator for Pgp and MRP-1. L-buthionine-sulfoximine 
(BSO) is a γ-glutamylcysteine synthase inhibitor and can be used to functionally decrease 
MRP-1 activity. 
Aim: In this study we aim to compare transport kinetics for human colorectal 
adenocarcinoma cell lines, one sensitive and another resistant to chemotherapy, in the 
presence and absence of MDR reversers, using 99mTc-Sestamibi. 
Methods: MDR proteins expression was evaluated in sensitive (WiDr) and resistant 
(LS1034) human colorectal adenocarcinoma cell lines. Intracellular and plasma membrane 
Pgp and MRP1, and LRP expression was analyzed by flow-cytometry; Pgp expression was 
also analyzed by western blot. Cellular transport kinetics was analyzed in the presence and 
absence of MDR modulators, verapamil and BSO, using 99mTc-Sestamibi. Uptake and 
retention studies were performed using sensitive and resistant cells. MDR modulation was 
evaluated by performing retention studies in resistant cells after incubation with the referred 
drugs, for different time intervals (10 and 60 minutes) and concentrations (10, 25, 50 and 
100 µM). 
Results: Pgp and MRP-1 expression was significantly higher (p<0.05) in resistant 
cells when comparing with the sensitive ones, although LRP was also expressed. Western blot 
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studies confirmed flow-cytometry results. 99mTc-Sestamibi uptake and retention percentage 
were significantly higher (p<0.05) in the sensitive cell line, comparing with the resistant one 
for all time-points considered. In resistant cells incubated with MDR modulators there were 
no statistically significant differences (p>0.05) when considering the curves as a whole. 
However, for the first minutes after incubation with 99mTc-Sestamibi, there were differences 
among the MDR modulators used.  
Conclusions: In vitro kinetic studies using 99mTc-Sestamibi could be an indicator of 
MDR phenotype in colorectal adenocarcinoma cells. As the modulators used showed a 
reversion of the retention profile only for the first minutes, their administration should occur 
immediately before the administration of cytotoxic drugs. 
 
Key-words: Multidrug resistance, P-glycoprotein, MRP-1, LRP, 99mTc-Sestamibi  
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Resumo 
Introdução: A multirresistência a fármacos (MDR) é definida pela resistência cruzada 
a diversos fármacos não relacionados estruturalmente, representando um dos principais 
factores de insucesso da quimioterapia. Um dos mecanismos mais estudados de MDR é a 
sobre-expressão de proteínas de efluxo, como a glicoproteína P (Pgp), a multiple resistance-
related protein-1 (MRP-1) e a major vault protein (LRP). A inibição farmacológica dos 
transportadores associados a MDR é a principal estratégia investigada para superar este 
fenótipo. O verapamil é um bloqueador dos canais de cálcio do tipo L e um modulador da Pgp 
e da MRP-1. A L-butionina-sulfoximina (BSO) é um inibidor da γ-glutamilcisteina sintetase e 
pode ser utilizada para diminuir a actividade funcional da MRP-1. 
Objectivo: Neste estudo pretendemos comparar a cinética de transporte para linhas 
celulares de adenocarcinoma colorrectal, uma sensível (WiDr) e outra resistente (LS1034), na 
presença e ausência de reversores de MDR, utilizando 99mTc-Sestamibi. 
Métodos: A expressão de proteínas MDR foi avaliada nas duas linhas celulares 
referidas. A expressão de Pgp e MRP-1 intracelular e membranar, e a expressão de LRP 
foram analisadas por citometria de fluxo; a expressão de Pgp foi também analisada por 
western blot. A cinética de transporte foi analisada na presença e ausência dos moduladores 
de MDR verapamil e BSO, usando 99mTc-Sestamibi. Foram efectuados estudos de captação e 
retenção utilizando células sensíveis e resistentes. A modulação de MDR foi avaliada pela 
realização de estudos de retenção em células resistentes após a incubação com os fármacos 
referidos, durante diferentes intervalos de tempo (10 e 60 minutos) e concentrações (10, 25, 
50 e 100 µM).  
Resultados: A expressão de Pgp e MRP-1 foi significativamente superior (p<0,05) 
nas células resistentes, embora a LRP também estivesse expressa. Os estudos de western blot 
confirmaram os resultados da citometria de fluxo. A captação e retenção de 99mTc-Sestamibi 
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foram significativamente superiores (p<0,05) na linha celular sensível para todos os tempos 
de amostra considerados. Nas células resistentes incubadas com moduladores de MDR não 
houve diferenças estatisticamente significativas (p>0,05) quando se consideraram as curvas 
como um todo. No entanto, para os primeiros minutos após a incubação com 99mTc-Sestamibi, 
houve diferenças entre as células incubadas com os moduladores. 
Conclusões: Estudos cinéticos in vitro com 99mTc-sestamibi podem ser um indicador 
de fenótipo MDR em células de adenocarcinoma colorrectal. Como os moduladores usados 
apenas mostraram reversão do perfil de retenção para os primeiros minutos, a sua 
administração deverá ser feita imediatamente antes da administração de citotóxicos. 
 
Palavras-chave: Multirresistência a fármacos, Glicoproteína-P, MRP-1, LRP,    
99mTc-Sestamibi 
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Introduction: 
Multidrug resistance (MDR) is a condition defined by the cross-resistance to several 
non-structurally related drugs. It represents one of the major setbacks to the success of 
chemotherapy, as drugs do not take effect on tumor cells. It was observed in several 
hematologic and solid tumors [1]. 
Several mechanisms have been described to explain this phenomenon: (1) changes in 
drug and plasma membrane interaction, (2) drug metabolism modifications, (3) intracellular 
drug sequestration, (4) development of DNA repair mechanisms, (5) evasion of drug-induced 
apoptosis, (6) expression of vault particles, (7) changes in tumor microenvironment and/or (8) 
expression of cancer stem cells, which acquire most of the previous mechanisms [2]. 
One of the best studied MDR mechanisms is the overexpression of efflux pumps, such 
as those belonging to the ATP-binding cassette (ABC) transporters superfamilly [2]. 
ABC-transporters are preferentially expressed in plasma membranes, although they are 
also expressed in several intracellular organelles. Seven ABC-subfamilies have been 
described in humans, labeled from ABCA to ABCG [2,3]. 
These proteins are present in blood-brain barrier, blood-testis barrier, placenta, 
gastrointestinal tract, liver and kidney, playing an important role in the protection against 
xenobiotics and endogenous metabolites [2,3,4]. 
Fifteen ABC transporters, belonging to ABCB, ABCC and ABCG subfamilies, have 
been associated with MDR up to date [2]. The first one described was ABCB1, also known as      
P-glycoprotein (Pgp), a 170 kDa glycoprotein that transports several substrates against 
concentration gradients [5,6]. These not structurally-related substrates are hydrophobic, have 
a molecular mass between 300 and 2000 kDa and most of them are cationic at physiologic pH 
[7]. 
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Another ABC transporter associated with MDR, identified in 1992, is ABCC1, also 
known as multidrug resistance-related protein 1 (MRP-1) [8]. It has a molecular weight of 
190 kDa and recognizes most of the cytotoxic substrates that are recognized by ABCB1, 
despite only presenting a 15% homology with this pump. It also transports lipophilic anions 
as glutathione, sulfate or glucuronate conjugates and by co-transport with glutathione without 
conjugation [6,9,10]. 
Vaults are ribonucleoprotein complexes that have been detected in several organisms 
and are composed by different proteins. One of them, the major vault protein (MVP), 
discovered in 1993 and named lung resistance-related protein (LRP), has been associated with 
MDR as it is overexpressed in several resistant cell lines [11,12,13]. 
Pharmacologic inhibition of MDR transporters is the major strategy to overcome this 
phenotype. They can either be a substrate of these transporters, modulating their activity by 
competitive inhibition, or they can induce conformational changes in these proteins, 
preventing substrate recognition or ATP hydrolysis. Verapamil, an L-type calcium-channel 
blocker and a first generation MDR modulator, modulates ABCB1 and ABCC1 activity 
[14,15]. Other MDR modulators were developed aiming to reduce toxicity and increase 
efficacy [14]. 
Another way to functionally inhibit MDR pumps is depleting the cell from substrates 
essential to its function. L-buthionine-sulfoximine (BSO) is an inhibitor of γ-glutamylcysteine 
synthase, an enzyme involved in de novo glutathione synthesis. Consequently, the glutathione 
reduced levels within the cell lead to a lower activity of the glutathione-dependent pump 
ABCC1 [16]. 
99mTc-Sestamibi is a radiotracer used in myocardial perfusion studies. Its uptake 
occurs by passive diffusion due to transmembrane electric potential, and it accumulates in 
mitochondria [17]. This radiotracer is cationic and mildly lipophilic, which are common 
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characteristics of several substrates of MDR efllux pumps. Therefore 99mTc-Sestamibi could 
be a possible probe for functional activity of this type of proteins [18]. 
In this study we aim to compare transport kinetics for two human colorectal 
adenocarcinoma cell lines, one sensitive and another resistant to chemotherapy, in the 
presence and absence of MDR reversers, using 99mTc-Sestamibi. 
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Materials and Methods 
Cell Culture: Sensitive WiDr (CCL-218, ATCC) and resistant LS1034 (CRL-2158, 
ATCC) human colorectal adenocarcinoma cell lines were obtained from American Type 
Culture Collection (Rockville, MD, USA). These cell lines were cultured in 5% CO2 
atmosphere, at 37ºC using Dulbecco's Modified Eagle's medium (DMEM, Sigma) for WiDr 
cell line and Roswell Park Memorial Institute-1640 (RPMI-1640, Sigma) for LS1034 cell 
line, both supplemented with 10% fetal calf serum (Gibco) and 1% of antibiotic-antimycotic 
(Gibco 15240). 
 
MDR Characterization 
 Flow Cytometry: In order to study/characterize the expression of MDR proteins, 
membrane and intracellular Pgp and MRP-1 and intracellular LRP were assessed by flow 
cytometry (Santa Cruz biotechnology, Inc). The analysis was performed using a                  
six-parameter, four-color FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) 
equipped with a 15 nW argon laser. For each assay, 106 cells were used and data on at least 
10.000 events was collected using Cell Quest software (Becton Dickinson) and analyzed 
using Paint-a-gate software (Becton Dickinson). 
 Western Blot: Both cell lines were cultured in 25mm Petri dishes in order to prepare 
the protein extracts. Cells were washed twice with cold phosphate buffer saline (PBS; in mM: 
137 NaCl, 2.7 KCl, 10 Na2HPO4, and 1.8 KH2PO4 [pH 7.4]), and lysed in Ripa buffer (150 
mM NaCl, 50 mM Tris, 5 mM EGTA, 1% Triton X-100, 0.5% DOC, 0.1% SDS) 
supplemented with complete miniprotease inhibitor cocktail tablets (cOmplete Mini, 
11836153001, Roche). 
 Protein concentration was determined by bicinchoninic acid (BCA) protein assay 
(Pierce Biotechnology, Rockford, IL, USA) and samples containing equal amount of protein 
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were used for immunoblots, after adding 6x concentrated sample buffer (0.5 M Tris, 30% 
glycerol, 10% SDS, 0.6 M dithiothreitol [DTT], 0.012% bromophenol blue) and heating the 
samples for 5 minutes at 95°C. Proteins were separated by 8% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and transferred electrophoretically to 
polyvivylidene fluoride membrane (Amersham HybondTM-P, GE Healthecare). Prestained 
molecular weight marker proteins were used as standards for the SDS–PAGE. A ponceau 
staining was performed to verify the quality of the transfer. The membranes were blocked for 
1 hour at room temperature in PBS containing 0.1% Tween-20 (TBS-T) and 5% low-fat milk. 
Incubation with the primary antibodies (Anti-P-Glycoprotein Mouse monoclonal antibody, 
517310 from Calbiochem) was performed overnight at 4°C. After washing for 1 hour in  
TBS-T with 0.5% low-fat milk, the membranes were incubated for 1 hour at room 
temperature with an alkaline phosphatase-linked secondary antibody (anti-mouse IgG+IgM, 
NIF1316 from Sigma, 1:20,000 in TBS-T with 1% low fat milk). Immunoblots were 
developed using the Enhanced Chemi-Fluorescence system (ECF; GE Healthcare) and a 
Storm device (Molecular Dynamics, GE Healthcare). The membranes were then reprobed and 
tested for β-actin immunoreactivity (Anti-β-Actin Mouse monoclonal antibody, A5441 from 
Sigma, 1:5,000) to prove that similar amounts of protein were applied in the gels. 
 
Kinetic Studies 
Preparation and Quality Control of 99mTc-Sestamibi: 99mTc-Sestamibi 
(Cardiolite®, Bristol-Meyers and Squibb) was prepared by reconstitution of a sterile 
lyophilized kit formulation. This kit was reconstituted with 1480 MBq of sterile sodium 
pertechnetate to a final radioactive concentration of 370 MBq/ml. The radiochemical purity 
was determined by ascending microchromatography using Baker-Flex #1 B-F (J.T. Baker, 
USA) as stationary phase and ethanol as mobile phase. The radiopharmaceutical was spotted 
 6 
 
approximately 1 cm from the bottom of the strip after spotting first in the same application 
point with an ethanol drop.  
Uptake Studies: To perform uptake cell studies, cells were washed with PBS, then 
harvested with a solution of 0.25% trypsin/EDTA and finally re-suspended in medium at 
2×106 cells/ml in 25 cm2 flasks. The flask was incubated at 37°C in 95% O2 and 5% CO2 
during one hour.  
Subsequently, 99mTc-Sestamibi was introduced in the medium at 2×106 cells/0.2 
MBq/ml after achieving steady state conditions. Triplicate samples of 200 µL were removed 
to eppendorfs containing chilled PBS for determination of tracer uptake at 5, 15, 30, 60, 90 
and 120 min. During tracer uptake studies, for every sample token, cells were re-suspended in 
order to ensure uniformity. Cell suspensions were then centrifuged at 10.000 rpm for 1 min, 
followed by aspiration of the supernatant. Radioactivity of cell pellets and supernatants were 
measured separately with a well-type gamma counter (DPC Gamma C12) to determine 
tracers’ uptake percentage in the cells. Cell viability was assessed by trypan blue exclusion 
test at the conclusion of experiments.  
Retention Studies: To perform retention studies the cells were submitted to the same 
procedures as described before. After achieving steady state conditions, the 
radiopharmaceutical was added so that cells could uptake 99mTc-Sestamibi during one hour. 
After this, cells were centrifuged at 1000 rpm for 5 min at 4ºC, followed by the aspiration of 
the supernatant that was replaced by radiopharmaceutical free medium. Triplicate samples of 
200 µL were removed to eppendorfs containing chilled PBS for determination of tracer 
retention at 1, 2.5, 5, 10, 15, 30, 45, 60, 90 and 120 min. Cell suspensions were then 
centrifuged at 10.000 rpm for 1 min, followed by aspiration of the supernatant. Radioactivity 
of cell pellets and supernatants were measured separately with a well-type gamma counter 
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(DPC Gamma C12) to determine tracers’ uptake percentage in the cells. Cell viability was 
assessed by trypan blue exclusion test at the conclusion of experiments. 
 
Cell Proliferation Assays 
To perform cytotoxicity studies, cells were grown to 90% confluence and harvested by 
treating with 0.25% trypsin with 0.02% EDTA. For each experiment, cells were plated in 24 
multiwells (Corning Costar Corp), in a concentration of 50.000cells/mL and kept in the 
incubator overnight, in order to allow their attachment. Cell plates were then incubated with 
different concentrations of verapamil (Sigma V4629) and BSO (L-Buthionine-sulfoximine, 
Sigma B2515), ranging from 1 to 200 µM. 
For every experiment two controls were performed, no treatment cells and cells 
incubated with the vehicle of administration of the drugs alone, which is dimethyl sulfoxide 
(DMSO, D8418) for verapamil and water for BSO. Each experiment was performed in 
duplicate and repeated in three sets of tests. 
The sensitivity of the cell lines to the previously referred drugs was accessed using the 
MTT colorimetric assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 
Sigma–Aldrich, Inc.; Sigma M2128) to measure cell proliferation. Yellow MTT is reduced to 
purple formazan in the mitochondria of living cells [19]. Therefore, the purple formazan 
products formation can be quantified measuring absorbance at the wavelength of 570 nm. 
Cytotoxicity was expressed as the percentage of inhibition of cell proliferation 
correlated with the cultures treated with the vehicle of administration for each drug. This 
procedure allows the determination of the concentration that inhibits the culture cell 
proliferation in 50% (IC50), which was determined using OriginPro, version 7. 
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MDR modulation 
To evaluate MDR modulation, retention studies were performed in the resistant cell 
line (LS1034) in the presence of verapamil and BSO prior to incubation with 99mTc-Sestamibi. 
The procedure used was the same as described before; however, after achieving steady state 
conditions and before adding the radiopharmaceutical to the cells, they were incubated for 
different periods of time (10 and 60 minutes) with different concentrations of the referred 
drugs (ranging from 10 to 100µM). These different conditions are summarized in Table I. 
Drug 
Period 
of incubation 
Verapamil BSO 
10 minutes 25µM 
50µM 
100µM 
10µM 
50µM 
100µM 60 minutes 
Table I: Concentrations and incubation periods for each drug used in retention studies for MDR modulation. 
 
Statistical analysis 
Results were analysed using Statistica package, version 7 and SPSS, version 16, at a 
significance level of 5%. For kinetic studies, time curves were compared as a whole by 
applying the general linear model (repeated measures ANOVA within time and one factor: 
incubation condition). For each time point, each condition was compared using one factor 
ANOVA test, with a post-hoc analysis using Tuckey’s method. To compare flow cytometry 
data we used Student’s t test for two independent samples, after confirming normal 
distribution by the Kolmogorov-Smirnov test. 
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Results 
Flow Cytometry 
Pgp expression analysed with flow cytometry was significantly higher (p<0.05) in the 
resistant cell line, when comparing to the sensitive one, both in the plasma membrane and 
intracellular organelles. MRP-1 expression in plasma membrane was also significantly higher 
in the resistant cell line (p<0.05). There were no statistical differences (p>0.05) between the 
two cell lines regarding to LRP and intracellular MRP-1 expression. Fluorescence intensity 
average (FIA) for each of the studied proteins is represented in Fig.1. 
 
 
 
 
 
 
 
Fig. 1: Expression of Pgp (A), MRP-1 (B) and LRP (C) assessed by flow cytometry. Bars represent fluorescence 
intensity average (FIA). Error lines represent standard deviation. 
 
 
B 
C 
A 
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Western Blot 
Pgp expression was also analysed using Western Blot techniques. Equal amounts of 
protein extracts from the two colorectal adenocarcinoma cell lines were applied into the gel. 
Incubation with anti-Pgp antibody showed a higher intensity of staining in the resistant cell 
line for a molecular weight of 170 kDa, which is consistent with a higher expression of Pgp 
(Fig.2A). Incubation with anti-β-Actin antibody confirmed that similar amounts of protein 
were applied in the gel, as the staining intensity was similar in both cell lines (Fig.2B). 
 
 
Fig. 2: Western blot membrane after incubation with anti-Pgp (A) and anti-actin (B) antibodies. In this 
membrane there are samples of WiDr and LS1034. Wells 1, 2 and 3 correspond to WiDr, LS1034 and 
weight control, respectively. 
 
Kinetic studies without modulators 
Uptake studies  
Uptake time curves for WiDr and LS1034 cell lines are represented in Fig.3A. An 
uptake peak can be observed after 60 minutes of incubation of WiDr with 99mTc-Sestamibi, 
with an average uptake percentage of 18.86% and a standard deviation of 6.49%. For LS1034, 
uptake percentage was mostly constant, varying between 1.36% and 1.85%. When comparing 
the two cell lines there where observed statistically significant differences (p<0.05) for every 
time-point considered, as well as when considering the curve as a whole. 
2 3 1 
A 
2 3 1 
B 
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Cell viability, assessed by trypan-blue exclusion test, was higher than 85% for all 
performed assays. 
 
Retention studies  
Retention curves for both WiDr and LS1034 are represented in Fig.3B. There is a 
higher retention percentage for WiDr when comparing to LS1034 (p<0.05) for every time-
point considered, as well when considering the curve as a whole. Five minutes after 
incubation with 99mTc-sestamibi, sensitive cells showed a mean retention percentage of 
82.99%, with a standard deviation of 4.79% while the resistant ones showed a mean of 
24.75%, with a standard deviation of 5.82%. After one hour, both curves almost overlap at 
approximately steady retention percentages, with mean values of 6.51% for WiDr and 3.42% 
for LS1034. 
Cell viability, assessed by trypan-blue exclusion test, was higher than 85% for all 
performed assays. 
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Fig.3: Uptake curves (A) and retention curves (B) obtained through 99mTc-Sestamibi for WiDr and LS1034 cell 
lines. Curves represent retention percentage through time. Error lines represent standard deviation for 
each time point considered. 
 
Cell proliferation assays using MDR modulators 
MTT assays were performed in LS1034 cell line using verapamil and BSO, in 
concentrations ranging from 1 to 200µM. Proliferation percentage correlated to control was 
determined at for 24h, 48h, 72h and 92h of incubation. Cytotoxicity curves were drawn and 
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IC50 was determined for each drug and period of incubation. IC50 values are shown in 
Table II. 
Drug 
Incubation 
Verapamil BSO 
24h 90,0 ± 10,88 µM >200 µM 
48h 39,0 ± 6,76 µM >200 µM 
72h 28,4 ± 8,00 µM >200 µM 
96h 26,6 ± 4,20 µM >200 µM 
Table II: IC50 values obtained for LS1034 cells incubated with Verapamil and BSO for periods of time of 24h, 
48h, 72h and 96h. 
 
Proliferation obtained for all BSO concentrations tested was similar to that of the 
control well; therefore, IC50 for this drug was not determined for LS1034 cell line. 
 
Retention studies using MDR modulators 
Retention curves obtained are shown in Fig.4. 
Incubation with verapamil (Fig.4A): Regarding the curves as a whole, there were no 
statistically significant differences (p>0.05) between the conditions studied. However, 
considering time-points of 1, 2.5 and 5 minutes, there were significant differences (p<0.05) 
between those conditions, that are due to a lower retention in cells that were not incubated 
with the modulator. There were no differences between different concentrations or periods of 
incubation for any of the time-points considered. 
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Incubation with BSO (Fig.4B): Considering all the time-points, there are no 
statistical differences (p>0.05) between the conditions studied. However, for time-points of 1, 
2.5 and 5 min there were differences between the retention percentages of those conditions, 
which as lower for LS1034 cell line incubated without the modulator.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Retention curves to study MDR modulation for LS1034, using verapamil (A) and BSO (B). Curves 
represent retention percentage through time. Error lines represent standard deviation for each time point 
considered. 
B 
A 
 15 
 
Discussion 
The main goal of this work was to evaluate the use of radioisotopic methods to 
identify resistance mechanisms mediated by efflux pumps, using 99mTc-Sestamibi. This 
radiotracer is cationic and hydrophobic, similar to the characteristics of ABC-transporters 
substrates [7]. Therefore the expression of these proteins in tumor cells may influence the 
uptake and efflux kinetics of 99mTc-Sestamibi and, in this case, this radiotracer could give 
information about their expression and become an important diagnosis tool. 
In this study we first evaluated MDR proteins expression in two colorectal 
adenocarcinoma cell lines, one of them known to be sensitive (WiDr) and other resistant 
(LS1034) to chemotherapy. Resistance to treatment with 5-fluorouracil (5-FU), the first 
choice for colorectal adenocarcinoma chemotherapy, is common [20]. Resistance to 
oxaliplatin and irinotecan, two drugs also used in the treatment of this type of cancer, is also 
described, being the last one a known substrate for MRP-1 [21,22].  It is therefore useful to 
evaluate the types of resistance mechanisms that are present in these types of tumors. As 
ABC-transporters are expressed in normal intestinal epithelial cells [23], this could represent 
a resistance mechanism in colorectal adenocarcinoma. 
After characterizing MDR proteins expression, we accessed if 99mTc-Sestamibi could 
be used as a probe for their expression in our cells lines. Its uptake and efflux kinetics could 
be influenced by the expression of these proteins but also by mitochondria density within the 
cell and physical properties of the membrane. We compared uptake and retention curves in 
both the sensitive and the resistant cell line in order to determine if 99mTc-Sestamibi is a good 
probe for MDR in colorectal adenocarcinoma cell lines. The same studies were performed 
using different modulators of ABC-transporters, in order to access MDR reversion in the 
resistant cell line. 
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MDR proteins expression 
Flow cytometry analysis of Pgp, MRP-1 and LRP expression showed that the resistant 
cell line LS1034 overexpressed Pgp and MRP-1 in the plasma membrane, as well as Pgp in 
intracellular organelles. This finding confirms the resistant phenotype described for this cell 
line, the association of Pgp and MRP-1 overexpression with MDR as been well established by 
different studies using cell lines [3].  
Western blot was used to confirm Pgp expression in cellular membranes for both cell 
lines. The comparison between different samples is done by observing staining intensity for 
the molecular weight of Pgp (170 kDa). Our results showed that LS1034 cells express Pgp. 
The staining intensity in the sensitive cell line, WiDr cells, was inexistent. β-actin staining 
confirmed that equal amounts of protein were applied into the gel, making the direct 
comparison between samples possible. These results are consistent with those obtained by 
flow cytometry, confirming the overexpression of Pgp in the resistant cell line and, therefore, 
its resistant phenotype. 
 
Kinetic studies 
Although Pgp and MRP-1 only have 15% of homology in aminoacid sequence [15] 
and have different transport mechanisms, it is known that these proteins transport a similar 
spectrum of substrates [9], being 99mTc-Sestamibi one of them [18,24]. 
Uptake kinetic studies using 99mTc-Sestamibi showed a higher uptake in WiDr when 
compared with that of LS1034. This radiopharmaceutical’s uptake occurs by passive diffusion 
and due to transmembrane electric potential, accumulating also in mitochondria [17]. 
However, when cells are resistant, efflux occurs simultaneously with uptake, not allowing 
99mTc-Sestamibi to diffuse into the mitochodria, which can lead to a lower uptake percentage 
of this radiotracer in cells which overexpress ABC-transporters. Therefore, the higher 
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expression of Pgp and MRP-1 in LS1034 cell line can justify the lower uptake percentage 
observed in kinetic studies. These results are consistent with those described in literature for 
other cell lines [18,25,26,27,28,29,30,31]. 
Retention studies using the same radiopharmaceutical showed a lower retention 
percentage for the resistant cell line, with a faster extrusion from the cell. This result is also 
correlated with the higher expression of ABC-transporters observed in LS1034 cell line, as 
their overexpression could lead to a faster and ATP-dependent efflux of 99mTc-Sestamibi. 
These results are consistent with those found on literature [18,25]. The faster extrusion 
observed for 99mTc-Sestamibi is related to the resistant phenotype described for these cells, as 
cytotoxic drugs could also be transported out of the cell before having the desired effect. 
 
MDR modulation evaluation 
The main strategy to overcome MDR is the use of modulators and/or inhibitors of 
efflux pumps. In this study we used a first generation MDR modulator, verapamil, a substrate 
for Pgp known to modulate its activity by competitive inhibition, as well as MRP-1 function 
[25,32]. We also used a γ−glutamylcysteine synthase inhibitor, BSO, in order to inhibit  
MRP-1 function, as it depends on glutathione to transport many substrates. 
Retention studies using these modulators showed a difference in the retention 
percentage between the resistant cells incubated without any modulator and those incubated 
with one of the previously referred drugs, for the first five minutes after incubation with 
99mTc-Sestamibi. However, retention curves tend to overlap, as the studies proceeds. This 
result could represent a reversion for the first minutes after incubation and does not seem to 
be dependent on time of incubation with the modulator or its concentration, for both drugs 
used.  
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Utsunomiya et al. performed retention studies in a nasopharyngeal carcinoma cell line, 
in the presence and absence of several MDR modulators, including verapamil and BSO, using 
99mTc-Sestamibi. Incubation with both these modulators resulted in a lower efflux percentage 
at 20 min after incubation with the radiotracer, comparing to control cells [33]. Studies 
performed by Gomes et al. in osteosarcoma cell lines also showed higher 99mTc-Sestamibi 
retention through time in cells incubated with these modulators, when comparing to controls 
[25]. In our study, however, the reversion induced by these two modulators was only verified 
for a short period of time. This could be explained by the involvement of additional 
transporters in efflux of this radiotracer, leading to a lower reversion on the retention rate in 
LS1034 cells. 
Another factor that may influence the results obtained is the period of incubation with 
BSO. Its mechanism of action is the depletion of glutathione, therefore inhibiting the function 
of MRP-1 [16]. A higher period of incubation could be necessary to deplete glutathione 
within the cell in a higher grade, so that a better reversion of MDR could be seen in these 
cells, as they express MRP-1. Meijer et al. described that after 24h of incubation with BSO, 
glutathione is no longer present within several different cells, without growth delay or loss of 
viability [34]. Studies using BSO as a MDR reverser used this drug for periods of incubation 
of 24h or incubation overnight [24,26,33]. Therefore, a similar period of incubation with BSO 
in our cell line could perhaps result in a more significant reversion of MDR. 
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Conclusions: 
In this study we observed that MDR proteins Pgp and MRP-1 are overexpressed in the 
colorectal adenocarcinoma resistant cell line LS1034, when comparing to sensitive WiDr 
cells. This result was confirmed using two different techniques, flow cytometry and western 
blot. 
Kinetic studies comparing both cell lines showed a lower uptake and retention 
percentages of 99mTc-Sestamibi in the resistant cell line LS1034, which are related to the 
higher expression of efflux pumps in this cell line, as these proteins can promote a fast 
extrusion of different substrates, including 99mTc-Sestamibi. 
Regarding MDR modulation retention studies performed in resistant cells, we 
observed a higher retention percentage in cells incubated with verapamil and BSO for the 
initial minutes, when comparing to that observed in the same cells incubated without any of 
the modulators. Retention curves tended to overlap over time, indicating that these findings 
could represent a reversion for the initial minutes after incubation with the radiotracer, which 
does not seem to depend on time of incubation or concentration of any of the modulators 
used. 
In summary, we established a correlation between efflux pumps expression and the 
retention of 99mTc-Sestamibi within colorectal adenocarcinoma cell lines. Therefore, in vitro 
kinetic studies could indicate MDR phenotype in this type of cells. 
As the modulators used during these experiments showed a reversion of the retention 
profile only for the first minutes of the retention studies, their administration should occur 
immediately before the administration of cytotoxic drugs. 
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Future perspectives 
In this study we compared two different cell lines, one sensitive and one resistant to 
chemotherapy. In future studies it would be important characterize MDR in resistant 
adenocarcinoma cells obtained by exposing the sensitive ones, WiDr cells, to increasing 
concentrations of 5-fluorouracil, oxaliplatin and irinotecan, three of the most used cytotoxic 
drugs in the treatment of these types of tumours. This would minimize the influence of other 
factors in the kinetics of 99mTc-Sestamibi uptake and efflux, such as plasma membrane 
fluidity, that could be different in our cell lines, giving their different origin. I would also be 
important to study the actual reversion of MDR using verapamil and BSO by performing 
cytotoxicity assays using the different chemotherapeutical agents referred before. 
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